Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: September 2026
Principal Executive Office: Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance updates rather than financial performance data.
Material Changes
The primary material change disclosed is a Change of Director's Interest regarding an individual named Stamler, as detailed in Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves solely to incorporate a director's interest notice into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the specific nature and magnitude of the change in Director Stamler's interest via Exhibit 99.1.
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential capital raising activities.
- Review the company's most recent Form 20-F for comprehensive financial data, as this 6-K contains no financial statements.